Beckley Psytech Takes On Rare Disease With Psychedelics

12 May 2022

• By Ayisha Sharma

Emerging Company Profile: The British biotech, co-founded by experimental researcher Lady Amanda Feilding, is developing psychedelics therapeutics for a rare but debilitating headache disorder and mental health disorders.

Beckley Psytech Wants To Help Tackle The Mental Health Crisis • Source: Shutterstock

With backing from high net-worth individuals and venture funds, Beckley Psytech, which was co-founded by Lady Amanda Feilding, is on a mission to treat rare diseases and mental health conditions with novel psychedelic compounds.

Feilding was famed for her experimental approach to psychiatric research during the 1960s and 70s, from micro-dosing LSD to trepanning,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Eolo Pharma Advances In Obesity With Thermogenesis Approach

04 Jul 2025

• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

Immusoft Goes For Cell Therapy Plan ‘B’

26 Feb 2025

• By Alaric DeArment

Emerging Company Profile: CEO Sean Ainsworth spoke with Scrip about how the company is developing B-cell therapies to treat a range of diseases, starting with MPS I.

Sanofi-Backed Resalis Brings MicroRNA To Obesity

29 Nov 2024

• By Elizabeth Cairns

Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.

Volastra Aims To Terminate Cancer Relying On Chromosomal Instability

01 Nov 2024

• By Jessica Merrill

Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

09 Jul 2025

• By Andrew McConaghie

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.